prof. dr. Emile Voest |
 prof. dr. Emile Voest is een toonaangevend oncoloog en verbonden aan het UMC Utrecht. Een citaat uit een e-mail van Emile:Hoewel statistieken over kanker natuurlijk relevant zijn zou ik in de beperkte tijd liever de blik op de toekomst willen richten. De vraag 'Hoe kunnen we elkaar helpen en inspireren in de strijd tegen kanker' die je stelt sluit hier prima op aan: Waarom ben ik als oncoloog zo positief over de vooruitgang die we boeken terwijl patienten dat nog niet heel erg merken, welke stappen worden er genomen? Biografie Emile Voest Emile Voest was registered as a medical doctor in 1985. He became board certified as an internist July 1993, and as a medical oncologist in January 1995. He completed his PhD program on the enhancement of the efficacy of anthracyclines by modulation of iron metabolism in tumor cells June 1993 (cum laude). In 1994 and 1995 he was a postdoctoral fellow of the Dutch Cancer Society. As a postdoctoral fellow he joined the laboratory of Dr. Judah Folkman, Children's Hospital, Harvard Medical School, Boston and worked on endogenous inhibitors of angiogenesis. Thereafter he worked at the Netherlands Cancer Institute in Amsterdam on high dose chemotherapy. January 1996 he became a staff member of the Department of Medical Oncology at the University Medical Center Utrecht. January 1997 he was appointed head of the Laboratory of Medical Oncology at the University Medical Centre Utrecht. November 1999 he became a full professor in Medical Oncology and head of the department of Medical Oncology at the University Medical Centre Utrecht. In addition, he was co-director of the Research Institute “Oncology and Developmental Biology” and board member of the graduate school of Developmental Biology of the Royal Dutch Academy of Sciences until 2006. He currently is director of the Oncology Research Program of the UMC Utrecht, board member of the scientific advisory board of the Dutch Cancer Society and serves in a variety of scientific committees and advisory boards. He has 6 patents to his name in the field of angiogenesis and biomarkers. The department of Medical Oncology at the UMC Utrecht has several preclinical and translational research lines including mitotic checkpoints, von Hippel Lindau tumor suppressor gene function and angiogenesis. The angiogenesis program includes the development and validation of biomarkers as predictive factors of therapy, the development of animal models (e.g. zebrafish), and a large early clinical trials program with a focus on antiangiogenic and other targeted therapies. Emile Voest is also heading the phase I program at the UMC Utrecht with a devoted team of nurses, scientists, data managers and clinicians. The preclinical research program and the early clinical trial program are mutually supportive and have a strong interaction. |